Peptide Lab HQ Research Guide
Semaglutide
A research-focused compound profile covering Semaglutide identity, GLP-1 receptor agonist research, incretin pathway signaling, glucose metabolism, appetite and satiety research, body-weight research context, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Semaglutide |
|---|---|
| Common Research Names | Semaglutide, GLP-1 analog, GLP-1 receptor agonist, Ozempic active ingredient, Wegovy active ingredient, Rybelsus active ingredient |
| Compound Type | Modified incretin peptide / long-acting GLP-1 receptor agonist research compound |
| CAS Number | 910463-68-2; verify against supplier COA |
| PubChem CID | 56843331 |
| Amino Acid Length | 31-amino-acid GLP-1 analog backbone with amino-acid substitutions and fatty-acid side-chain modification |
| Modified Sequence Context | His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 fatty di-acid spacer)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| Structural Feature | Modified at position 8 for DPP-4 stability, modified at Lys26 with a hydrophilic spacer and C18 fatty di-acid for albumin binding, and modified at position 34 to support single fatty-acid attachment |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉; verify against supplier COA |
| Molecular Weight | Approximately 4113.58 g/mol; verify against supplier COA |
| Research Category | GLP-1 receptor signaling, incretin pathway research, glucose metabolism, appetite signaling, gastric-emptying research, body-weight research, cardiovascular-risk research context, and MASH / liver-metabolism research |
| Research Context | Commonly discussed in controlled research involving glucose-dependent insulin secretion, glucagon suppression, appetite regulation, delayed gastric emptying, body-weight change, cardiovascular outcomes, and metabolic pathway documentation. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Semaglutide is commonly discussed in controlled research models involving GLP-1 receptor activity, glucose metabolism, insulin and glucagon signaling, appetite regulation, satiety response, gastric-emptying research, body-weight change, cardiovascular outcomes, and liver-metabolism research context.
GLP-1 Receptor Research
Semaglutide is studied as a GLP-1 receptor agonist designed to activate incretin-related signaling pathways with extended activity.
Glucose Metabolism Models
Used in research involving glucose-dependent insulin secretion, glucagon suppression, fasting glucose, HbA1c response, and type 2 diabetes study contexts.
Appetite & Satiety Research
Semaglutide is commonly discussed in research involving appetite regulation, reduced calorie intake, satiety signaling, food-intake behavior, and body-weight change.
Gastric Emptying Context
GLP-1 receptor agonist research commonly tracks delayed gastric emptying, gastrointestinal tolerability, absorption timing, and digestive-response markers.
Cardiovascular Outcomes Context
Semaglutide prescription-product research includes cardiovascular-risk reduction contexts, especially in populations with established cardiovascular disease and excess body weight.
MASH / Liver-Metabolism Research
Semaglutide is also discussed in metabolic liver-disease research involving liver fat, liver stiffness, fibrosis-related markers, inflammation, and weight-loss-associated metabolic changes.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on compound form, purity, concentration, receptor expression, model type, route, escalation schedule, metabolic status, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 2 mg Semaglutide |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 1 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 1 mg/mL, 1 unit equals 0.01 mg / 10 mcg Semaglutide. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear. Do not shake!
- For higher-concentration preparations, verify that the material is fully dissolved before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Semaglutide, GLP-1 receptor agonist research compound | Semaglutide is commonly discussed as a modified GLP-1 analog used in glucagon-like peptide-1 receptor signaling and incretin-pathway research contexts. |
| GLP-1 Receptor Research | GLP1R pathway context | Commonly discussed in GLP-1 receptor activation, incretin signaling, glucose-handling, insulin-response, appetite-response, and metabolic-marker research models. |
| Metabolic Research Context | Clinical-study context only | Semaglutide has been discussed in clinical-study contexts involving glycemic markers, body-weight markers, appetite-response, cardiometabolic markers, and metabolic-disease models. These clinical-study references are not research-chemical dosing standards. |
| Glucose / Insulin Marker Research | Model-dependent endocrine-marker tracking | Commonly discussed in glucose regulation, insulin secretion, insulin sensitivity, beta-cell response, and incretin-response research contexts. |
| Appetite / Energy-Balance Research | Experimental and clinical-marker context | Semaglutide-related research is often discussed in appetite signaling, food-intake behavior, gastric-emptying context, energy balance, and body-weight marker models. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references commonly describe Semaglutide in microgram-to-milligram examples depending on the research model and preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, clinical-study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 2 mg | 2.0 mL | 1 mg/mL |
| 5 mg | 2.0 mL | 2.5 mg/mL |
| 10 mg | 2.0 mL | 5 mg/mL |
| 15 mg | 3.0 mL | 5 mg/mL |
| 20 mg | 3.0 mL | 6.67 mg/mL |
| 30 mg | 3.0 mL | 10 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 1 mg/mL | U-100 Unit Reference | Approx. References per 2 mg Vial |
|---|---|---|---|
| 0.1 mg / 100 mcg | 0.10 mL | 10 units | 20 |
| 0.25 mg / 250 mcg | 0.25 mL | 25 units | 8 |
| 0.5 mg / 500 mcg | 0.50 mL | 50 units | 4 |
| 1 mg / 1000 mcg | 1.00 mL | 100 units | 2 |
| 2 mg / 2000 mcg | 2.00 mL | 200 units | 1 |
| 2.5 mg / 2500 mcg | 2.50 mL | 250 units | 0.8 |
| 5 mg / 5000 mcg | 5.00 mL | 500 units | 0.4 |
| 10 mg / 10000 mcg | 10.00 mL | 1000 units | 0.2 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Low Conversion Reference | Calculation reference only | 0.1 mg reference amount | 10 units / 0.10 mL |
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.25 mg reference amount | 25 units / 0.25 mL |
| Low-to-Mid Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 50 units / 0.50 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 100 units / 1.00 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 200 units / 2.00 mL |
| Upper Conversion Example | Calculation reference only | 2.5 mg reference amount | 250 units / 2.50 mL |
| High Conversion Example | Calculation reference only | 5 mg reference amount | 500 units / 5.00 mL |
| Preparation-Level Conversion Example | Calculation reference only | 10 mg reference amount | 1000 units / 10.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Receptor Observation Window | 24–72 hours | May be used for GLP-1 receptor signaling, incretin-pathway response, intracellular signaling, beta-cell marker, or glucose-handling pathway documentation depending on the model. |
| Acute Metabolic Observation Window | Single session to several days | Used for short-term glucose, insulin, appetite-response, endocrine-marker, receptor-response, or early pathway tracking depending on the research design. |
| Short Research Window | 1–4 weeks | May be used for early controlled observation involving glucose-handling markers, appetite-response markers, metabolic markers, or dose-ranging model documentation. |
| Standard Protocol-Style Window | 4–12 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 12–24 weeks or longer | Used when longer documentation is needed for body-weight, glycemic-marker, appetite-response, cardiometabolic, or follow-up marker tracking. |
| Follow-Up / Washout | 4–12 weeks | Used to document post-study observations, marker return, delayed response patterns, or return-to-baseline data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Semaglutide is commonly discussed in GLP-1 receptor, incretin-pathway, glucose-handling, insulin-response, appetite-response, glycemic-marker, body-weight, cardiometabolic, and metabolic-disease research contexts. The selector above updates calculations for 2 mg, 5 mg, and 10 mg vial references reconstituted with 2.0 mL bacteriostatic water, and 15 mg, 20 mg, and 30 mg vial references reconstituted with 3.0 mL bacteriostatic water. Published study references, clinical-study contexts, and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Semaglutide is commonly discussed in research involving GLP-1 receptor activity, glucose-dependent insulin secretion, glucagon suppression, appetite regulation, delayed gastric emptying, body-weight change, cardiovascular outcomes, and liver-metabolism markers.
Study Limitations
Semaglutide research includes prescription-product studies, metabolic disease research, cardiovascular outcome studies, obesity studies, oral tablet research, and MASH-related research. Findings should be interpreted according to compound form, route, dose-escalation design, study population, metabolic status, and endpoint selection.
Safety Considerations
Research discussion should account for gastrointestinal response, nausea, vomiting, diarrhea, constipation, delayed gastric emptying, pancreatitis context, gallbladder disease, dehydration-related kidney injury, hypoglycemia risk in diabetes contexts, diabetic retinopathy complications, heart-rate observations, peptide purity, sterility documentation, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.